Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint
about
In vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection modelPharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient PopulationsA Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground.Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa.A pharmacokinetic-pharmacodynamic (PKPD) model based on in vitro time-kill data predicts the in vivo PK/PD index of colistin.Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseasesPharmacokinetic-pharmacodynamic profiling of four antimicrobials against gram-negative bacteria collected from Shenyang, China.Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteersApplication of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhiPharmacokinetics of clindamycin in pregnant women in the peripartum period.Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenemPopulation pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosisEvaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations.Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy.Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimensWorldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study TeamPharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program.Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers.Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh modelDerivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effectApplication of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuisExposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.Setting and revising antibacterial susceptibility breakpoints.Antibiotic treatment for urinary tract infections: pharmacokinetic/pharmacodynamic principles.Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosisPharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation.Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemiaPharmacokinetics of penicillin G in infants with a gestational age of less than 32 weeks.Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents.Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa.Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the society of infectious diseases pharmacists.Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists.Pharmacokinetics and pharmacodynamics of antimicrobials.Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection
P2860
Q24654780-BE3205E9-C52B-49AE-9551-61960580BE31Q28066877-7B130AB0-048A-4BFB-A9C5-04C5D6FA3DF1Q30275728-E332138E-4C37-4705-A4A6-25BAD0B314CBQ30775587-1E99E06F-1442-4720-B825-621EC0CBC53BQ31059319-4C0E60AA-9574-4464-8C0D-A4948AC78AB3Q33236887-78B92699-63F8-4280-A1C1-BCA70841EF6CQ33603799-B551D99F-79D1-488A-B8C0-5978BB5C2625Q33676387-82E4AEA0-D49B-4B5B-B275-EAF8B0A3A9A6Q33769931-3EFD2F3C-2F63-4A3B-9B92-B2F66064ABFFQ33826411-7EEACD7E-2975-4076-B79E-A299F3327F50Q33935441-8E0D035C-2E57-4C0C-816B-68C87C372546Q33983611-695DE067-E4A6-4C96-9C84-B0E7C62FA535Q34077003-16C9F00D-E2E0-46CA-A5F0-F369B4E2C8BBQ34298988-FE4BD34D-A926-454F-B8F6-4D6DEDF0FEB2Q34307105-FD27C7C0-86DB-4ADE-A1ED-B3A49827C877Q34381321-896B52EB-B8E4-4B30-9F06-5936B23C773DQ34725279-5176FC5F-AF12-404E-B998-83B9844DEBDBQ34937147-4E493548-C252-47AB-819F-D404E7ABFC0BQ35005118-F26D56D1-8029-4B99-BA86-37379B3E14BBQ35106016-99D7CFAB-560B-4335-B097-A5DD4E64F1EAQ35127913-4E718E37-EEAC-4385-BD83-731B2D581C78Q35140423-F387B352-B680-4B0E-960A-2A6DF77D2B59Q35151557-EA1A3E9A-AE8A-4B31-8EF1-6C340ADB5879Q35840772-E364C272-D772-431C-A2CC-875DEE37850BQ35878860-42069580-868A-459E-83F2-6A6AA391C813Q35913176-0F2BF158-410A-4C60-BC03-FE450F7574B1Q35964763-1F4606DE-8385-4DDA-9978-A5479F712630Q36072639-EDE15582-1914-4E88-9E25-011D84B6B46EQ36086373-8ED5A04A-672C-45D6-AEE5-CF01484C292AQ36094883-C3D5FAD2-6DC5-42C6-A916-7E18BD2EB889Q36094911-2EF14986-9816-42FD-9CC1-DAADA54B0C7CQ36094974-3C4B3EAA-197B-4199-BF8C-2822EE9E71C5Q36095091-27487947-EA4F-4AED-A244-134871181E44Q36162355-F6105024-C03A-4D89-B4D4-CCF51968218AQ36313211-7F450D3A-E9B6-4664-BA5B-B5B51B5CE677Q36396244-15DD61A2-AE56-44A2-92FB-6C55F8DA1A90Q36408747-1F2A4E5E-F18B-417A-889E-45F14ABBD9D2Q36582692-E93C5E1F-B420-4C88-9E16-3A0826428F90Q36854798-02C3E000-6981-4A41-9786-6D81B8BC2130Q36879791-75DCECC4-61C8-454F-A9BF-2950D5613180
P2860
Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Use of preclinical data for se ...... f a preclinical MIC breakpoint
@ast
Use of preclinical data for se ...... f a preclinical MIC breakpoint
@en
type
label
Use of preclinical data for se ...... f a preclinical MIC breakpoint
@ast
Use of preclinical data for se ...... f a preclinical MIC breakpoint
@en
prefLabel
Use of preclinical data for se ...... f a preclinical MIC breakpoint
@ast
Use of preclinical data for se ...... f a preclinical MIC breakpoint
@en
P2093
P2860
P1476
Use of preclinical data for se ...... f a preclinical MIC breakpoint
@en
P2093
C Banfield
G L Drusano
S L Preston
P2860
P356
10.1128/AAC.45.1.13-22.2001
P407
P577
2001-01-01T00:00:00Z